hotspot -WSS

hotspot

author：knowledge 2025-09-27 22:49:11 - browse：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Elizabeth Warren probes abortion access

WSS

Body of missing toddler recovered in Delaware River days after flood: Police

Caitlin Bernard's story shows physicians can't shy from advocacy

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Friends ask where James Watson's attitudes about race came from

In new study, freeze

entertainment

hotspot

explore

Medical records are filled with copy

Elizabeth Warren probes abortion access

Affirmative action in medical school literally saved lives

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Psychedelics group wrestles with new pharma identity

Body of missing toddler recovered in Delaware River days after flood: Police

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Psychedelics group wrestles with new pharma identity

Court strikes down limits on filming of police in Arizona

leisure time

Why an extreme heat and wildfire smoke combination can be so dangerous

NIH trials fail to test meaningful long Covid therapies, experts say

In new study, freeze

In new study, freeze

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

focus

hotspot

Wikipedia

knowledge